Blood microRNA changes in depressed patients during antidepressant treatment

Eur Neuropsychopharmacol. 2013 Jul;23(7):602-11. doi: 10.1016/j.euroneuro.2012.06.013. Epub 2012 Aug 25.

Abstract

MicroRNAs (miRNAs) are potent modulators of protein expression that play key roles in brain pathways regulating neurogenesis and synaptic plasticity. These small RNAs may be critical for the pathophysiology of mental disorders and may influence the effectiveness of psychotropic drugs. To investigate the possible involvement of miRNAs in the mechanism of action of antidepressants (AD), we conducted a whole-miRNome quantitative analysis with qRT-PCR of the changes in the blood of 10 depressed subjects after 12 weeks of treatment with escitalopram. Thirty miRNAs were differentially expressed after the AD treatment: 28 miRNAs were up-regulated, and 2 miRNAs were strongly down-regulated. miRNA target gene prediction and functional annotation analysis showed that there was a significant enrichment in several pathways associated with neuronal brain function (such as neuroactive ligand-receptor interaction, axon guidance, long-term potentiation and depression), supporting the hypothesis that the differentially regulated miRNAs may be involved in the AD mechanism.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antidepressive Agents, Second-Generation / pharmacology*
  • Antidepressive Agents, Second-Generation / therapeutic use
  • Citalopram / pharmacology*
  • Citalopram / therapeutic use
  • Databases, Genetic
  • Depressive Disorder, Major / blood
  • Depressive Disorder, Major / drug therapy*
  • Female
  • Gene Expression Regulation / drug effects*
  • Humans
  • Male
  • MicroRNAs / blood
  • MicroRNAs / drug effects*
  • Middle Aged
  • Signal Transduction / genetics

Substances

  • Antidepressive Agents, Second-Generation
  • MicroRNAs
  • Citalopram